<DOC>
	<DOCNO>NCT00312039</DOCNO>
	<brief_summary>HIV-1 infect patient receive long-term therapy lamivudine emtricitabine ( nucleoside reverse transcriptase inhibitor [ NRTIs ] ) risk development mutation position M184 HIV reverse transcriptase gene . This mutation confers resistance drug ( &gt; 100 fold increase IC50 ) . In-vitro study elvucitabine show HIV-1 isolates M184V mutation show 10-fold increase IC50 compare wild type HIV-1 . Achillion Pharmaceutical 's intention demonstrate 10 mg elvucitabine , administer per day 14 day continue background anti-HIV-1 medication , demonstrate fall HIV-1 RNA plasma level , compare baseline . The data study guide dose future long-term study HIV-1 infect patient M184V mutation .</brief_summary>
	<brief_title>Study Once Daily Elvucitabine Versus Lamivudine Subjects With Documented M184V Mutation</brief_title>
	<detailed_description>Protocol Title : A 14-Day , Randomized , Double-Blind , Comparative Viral Kinetic Study Elvucitabine Versus Lamivudine Administered Once Daily HIV-1 Infected Subjects With Documented M184V Variant Protocol Number : ACH443-014A Clinical Phase : 2a Primary Objectives : • To assess viral kinetics 10 mg elvucitabine administer daily ( QD ) 14 day combination background antiretroviral therapy HIV-1-infected subject document M184V variant - To demonstrate antiviral activity 10 mg elvucitabine administer QD 14 day combination background antiretroviral therapy compare lamivudine combination background antiretroviral therapy HIV-1 infected subject document M184V variant - To assess safety elvucitabine therapy HIV-1 infected subject document M184V variant Number Subjects : 20 Number Study Centers : Multi-center study Study Population : HIV-1 infected subject presently fail antiretroviral therapy regimen contain lamivudine emtricitabine , genotypically demonstrate MI84V variant , HIV RNA plasma level ≥ 2,000 ≤ 150,000 copies/mL . Study Design : HIV-1 infected subject , document M184V variant , randomize receive elvucitabine 10 mg QD lamivudine 300 mg QD 14 day . Subjects must receive stable antiretroviral regimen ( defined change antiretroviral therapy least 4 week prior randomization ) include lamivudine emtricitabine . At 72 hour prior randomization , lamivudine emtricitabine stop washout ; subject continue receive drug prescribe regimen ( background antiretroviral therapy ) 72-hour washout period . Subjects randomize receive blind elvucitabine lamivudine 1:1 ratio continue receive prescribe background antiretroviral therapy 14 day outpatient basis . Subjects follow additional 14 day post-treatment safety , unless enroll ACH443-018 extension study continue treat follow safety .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Clinically stable HIV1 infect patient Ages &gt; 18 &lt; 65 year Documented M184V mutation CD4 cell count &gt; 100 cells/mL Plasma HIV1 RNA level &gt; 5000 &lt; 150,000 copies/mL Currently receive lamivudine emtricitabine Other hematologic metabolic parameter must meet . Provide write informed consent Other inclusion criterion apply . Hepatitis B antigen positive HIV1 genotype positive equal 4 protease mutation HIV1 genotype positive equal 2 nonnucleoside reverse transcriptase inhibitor ( NNRTI ) mutation Previous therapy cytotoxic myelosuppressive drug past 3 month Evidence history cirrhosis Women pregnant breast feed Other exclusion criterion apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>treatment experience</keyword>
</DOC>